Clinical Trial Update: Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC [Phase 3]

View source ↗

Summary

A phase 3 real-world trial assessing AZD9291 (osimertinib) for advanced/metastatic EGFR T790M mutation non-small cell lung cancer has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-10-25